As other major factors, the concentrations of reactive oxygen species (ROS) and glutathione (GSH) are extremely higher in TME (Cook et al., 2004), which allow different nano-agents to be applied for treating aggressive cancers including taxane resistant prostate cancer, erlotinib-resistant EGFR-mutated NSCLC cells and TNBC via redox-induced therapeutic functions (He et al., 2018; Dai et al., 2019; Hu et al., 2019; Lin et al., 2019; Liu et al., 2019b; Yang et al., 2019a; Zhang et al., 2019; Gao et al., 2020). This evidence concerns the gene EGFR and non-small cell lung carcinoma.